Heart transplant drug may also fight skin cancer
NCT ID NCT00799188
First seen Jan 05, 2026 · Last updated May 12, 2026 · Updated 19 times
Summary
This study tested whether the drug everolimus can reduce new skin cancers in heart transplant patients who already had skin cancer. 175 adults who had a heart transplant at least a year ago and had recurring skin cancers took part. The goal was to see if switching to everolimus would lead to fewer skin tumors needing surgery compared to standard anti-rejection drugs.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SKIN CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
HOSPICES CIVILS de LYON
Lyon, France
Conditions
Explore the condition pages connected to this study.